BACKGROUND: Low white blood cell counts (WBC) or absolute neutrophil counts (ANC) may delay or prevent the completion of appropriate chemotherapy, especially among women receiving adjuvant therapy for breast and colon cancer, and affect cancer survival. Because race/ethnicity is also associated with survival, the authors compared WBC and ANC in healthy American-born women of African descent and European descent, and women from Barbados/Trinidad-Tobago, the Dominican Republic, Haiti, and Jamaica. METHODS: Blood samples from 261 healthy women ages 20 to 70 years were tested for WBC with differential, cytokine and growth factor levels, and ancestry informative and neutrophil elastase polymorphisms. The authors analyzed the association between neutropenia and serum WBC growth factor levels, cytokine levels, and neutrophil elastase c199a polymorphism. RESULTS: The median WBC and ANC differed among the 6 groups (P < .01 for WBC and P < .0001 for ANC). Dominicans were found to have higher median WBC and ANC than all other groups (P < .03). Neutropenia (ANC < 1500 cu/mm) was observed among 2.7% to 12.5% of the groups of predominantly African descent; no other groups were found to have neutropenia (P < .05). Granulocyte-colony-stimulating factor was found to be lower in white women, but tumor necrosis factor-alpha and C-reactive protein were not found to be correlated with ethnicity. Women of African origin were more likely to have polymorphisms of African ancestry (P < .001) and c199a alleles (P < .0001), which were also associated with low ANC levels. CONCLUSIONS: In the current study, the authors observed a strong association between neutropenia and African descent among asymptomatic women from the U.S. and the Caribbean. Among women of African descent who develop a malignancy, this association may contribute to racial disparities in treatment and outcomes. 2008 American Cancer Society
BACKGROUND: Low white blood cell counts (WBC) or absolute neutrophil counts (ANC) may delay or prevent the completion of appropriate chemotherapy, especially among women receiving adjuvant therapy for breast and colon cancer, and affect cancer survival. Because race/ethnicity is also associated with survival, the authors compared WBC and ANC in healthy American-born women of African descent and European descent, and women from Barbados/Trinidad-Tobago, the Dominican Republic, Haiti, and Jamaica. METHODS: Blood samples from 261 healthy women ages 20 to 70 years were tested for WBC with differential, cytokine and growth factor levels, and ancestry informative and neutrophil elastase polymorphisms. The authors analyzed the association between neutropenia and serum WBC growth factor levels, cytokine levels, and neutrophil elastase c199a polymorphism. RESULTS: The median WBC and ANC differed among the 6 groups (P < .01 for WBC and P < .0001 for ANC). Dominicans were found to have higher median WBC and ANC than all other groups (P < .03). Neutropenia (ANC < 1500 cu/mm) was observed among 2.7% to 12.5% of the groups of predominantly African descent; no other groups were found to have neutropenia (P < .05). Granulocyte-colony-stimulating factor was found to be lower in white women, but tumor necrosis factor-alpha and C-reactive protein were not found to be correlated with ethnicity. Women of African origin were more likely to have polymorphisms of African ancestry (P < .001) and c199a alleles (P < .0001), which were also associated with low ANC levels. CONCLUSIONS: In the current study, the authors observed a strong association between neutropenia and African descent among asymptomatic women from the U.S. and the Caribbean. Among women of African descent who develop a malignancy, this association may contribute to racial disparities in treatment and outcomes. 2008 American Cancer Society
Authors: Weijing He; John Castiblanco; Elizabeth A Walter; Jason F Okulicz; Sunil K Ahuja Journal: Curr Opin HIV AIDS Date: 2010-11 Impact factor: 4.283
Authors: Deepti Jain; Chani J Hodonsky; Ursula M Schick; Jean V Morrison; Sharon Minnerath; Lisa Brown; Claudia Schurmann; Yongmei Liu; Paul L Auer; Cecelia A Laurie; Kent D Taylor; Brian L Browning; George Papanicolaou; Sharon R Browning; Ruth J F Loos; Kari E North; Bharat Thyagarajan; Cathy C Laurie; Timothy A Thornton; Tamar Sofer; Alexander P Reiner Journal: Hum Mol Genet Date: 2017-03-15 Impact factor: 6.150
Authors: Nelson L S Tang; Chen Di Liao; Xingyan Wang; Frankie K F Mo; Vicky T C Chan; Rita Ng; Elizabeth Pang; Joyce J S Suen; Jean Woo; Winnie Yeo Journal: J Cancer Res Clin Oncol Date: 2012-11-10 Impact factor: 4.553
Authors: Hemant Kulkarni; Vincent C Marconi; Weijing He; Michael L Landrum; Jason F Okulicz; Judith Delmar; Dickran Kazandjian; John Castiblanco; Seema S Ahuja; Edwina J Wright; Robin A Weiss; Robert A Clark; Matthew J Dolan; Sunil K Ahuja Journal: Blood Date: 2009-07-20 Impact factor: 22.113
Authors: Gina Kim; Jessica M Pastoriza; John S Condeelis; Joseph A Sparano; Panagiota S Filippou; George S Karagiannis; Maja H Oktay Journal: Front Oncol Date: 2020-06-30 Impact factor: 6.244
Authors: Victor R Grann; Elad Ziv; Cecil K Joseph; Alfred I Neugut; Ying Wei; Judith S Jacobson; Marshall S Horwitz; Natalie Bowman; Kenneth Beckmann; Dawn L Hershman Journal: Br J Haematol Date: 2008-08-15 Impact factor: 6.998